Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
Abstract Pemigatinib is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR)1–3 with efficacy in patients with previously treated, advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 alterations. A previously developed population pharmacokinetic (PK) model of pemigatin...
Main Authors: | Xiaohua Gong, Ayman Akil, Andre Ndi, Tao Ji, Xiang Liu, Mark Lovern, Xuejun Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13064 |
Similar Items
-
Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2022-10-01) -
Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
by: Tao Ji, et al.
Published: (2022-07-01) -
Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
by: Jonathan Wadsley, et al.
Published: (2023-08-01) -
Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
by: Daniel Walden, et al.
Published: (2022-08-01) -
Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
by: Zhuochao Zhang, et al.
Published: (2023-05-01)